COVID-19 Vaccine HIPRA
Sponsors
Hipra Scientific, S.L.U, Thammasat University Hospital
Conditions
COVID-19Healthy volunteers who had received 2 doses of ChAdOx-1 or heterozygous Sinovac- ChAdOx-1 more than 90 days.
COVID-19 vaccine, booster vaccinationSARS-CoV-2 Acute Respiratory Disease
Phase 2
Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)
CompletedNCT05142514
Start: 2021-11-11End: 2022-05-06Updated: 2024-02-26
Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.
CompletedNCT05142553
Start: 2021-11-16End: 2023-05-29Updated: 2026-03-11
The study of immunogenicity and safety of HIPRA COVID-19 Vaccine as the booster vaccination in individuals who had completed primary series of COVID vaccination
Active, not recruitingTCTR20220317003
Start: 2022-04-18Target: 444Updated: 2026-08-03